The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations

BJU International - Tập 103 Số 5 - Trang 572-577 - 2009
Joaquim Bellmunt1, Marta Guix1
1University Hospital del Mar, Barcelona, Spain

Tóm tắt

There are now five targeted agents, i.e. sorafenib, sunitinib, temsirolimus, bevacizumab (in combination with interferon) and everolimus, that have been shown to improve the outcome in patients with metastatic clear cell renal cell carcinoma (mRCC), in randomized controlled trials (RCTs). Compared with the period when cytokines were the only systemic intervention known to have any activity, decisions on medical management are now complex. Clinicians must seek to adjust therapy to the circumstances of the individual patient, and consider the sequencing of agents. In this context, several expert groups have sought to provide treatment guidelines. As in other diseases, guidelines for mRCC seek to establish evidence‐based recommendations for best clinical practice and to encourage their widespread use. Data from phase III trials (level 1 evidence) are an essential element in this process, and guidelines need continual updating in the light of new findings. However, there are inevitably questions that large RCTs have not directly addressed. This is the case for major subgroups of the mRCC population, e.g. the elderly and those with comorbidities. In these circumstances, less well‐controlled sources of data, and clinical experience, have a role to play. Certain guidelines (although not all) acknowledge the contribution that such sources of evidence can make.

Từ khóa


Tài liệu tham khảo

10.1093/annonc/mdl498

10.3322/canjclin.56.2.106

10.1016/j.eururo.2007.03.035

10.1016/j.ctrv.2007.12.001

National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Available at:http://www.nccn.org. Accessed August 2008

10.1002/14651858.CD001425

Bukowski R, 2007, Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis, J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.5023

10.1056/NEJMoa060655

10.1016/S0140-6736(07)61904-7

Figlin RA, 2008, Overall survival with sunitinib versus interferon (IFN) ‐alfa as first‐line treatment of metastatic renal cell carcinoma (mRCC), J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.5024

10.1056/NEJMoa066838

10.1056/NEJMoa065044

10.1016/S0140-6736(08)61039-9

RiniBI HalabiS RosenbergJEet al.CALGB 90206. A Phase III trial of bevacizumab plus interferon‐alpha versus interferon‐alpha monotherapy in metastatic renal cell carcinoma.ASCO Genitourinary Cancers Symposium2008; Abstract 5033

10.1200/JCO.2001.19.11.2886

De ReijkeTM BellmuntJ Van PoppelH MarreaudS AaproM.EORTC‐GU group expert opinion on metastatic renal cell cancer.Eur J Cancer2008(in press)

10.1016/j.critrevonc.2008.08.002

10.1016/j.eururo.2005.11.035

Canadian Kidney Cancer Forum., 2008, Management of kidney cancer. Canadian Kidney Cancer Forum Consensus Statement, Can Urol Assoc J, 2, 175

10.1016/S1166-7087(07)74782-6

Norwegian Directorate of Health.Nasjonalt handlingsprogram med retningslinjer for diagnostikk behandling og oppfølging av pasienter med nyrecellekreft. Available at:http://www.shdir.no. Accessed August 2008

Dham A, 2007, Sequential therapy with sorafenib and sunitinib in renal cell carcinoma, J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.5106

Sablin MP, 2007, Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients, J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.5038

EscudierB RavaudA BracardaSet al.Efficacy and safety of first‐line bevacizumab (BEV) plus interferon‐a2a (IFN) in subgroups of patients (pts) with metastatic renal cell carcinoma (mRCC).ASCO Genitourinary Cancers Symposium2008; Abstract 358

Dutcher JP, 2007, Correlation of survival with tumor histology, age and prognostic risk group for previously treated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon‐alpha (IFN), J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.5033

Bukowski RM, 2008, Safety and efficacy of sorafenib in elderly patients (pts) >65 years: a subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America, J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.5045

EisenT OudardS SzczylikCet al.Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma: subgroup analysis of The Approaches in Renal Cancer Global Evaluation Trial (TARGETs).22nd Annual EAU Congress2008 abstract 964

RiniBI.Renal Cell Carcinoma: What Really Matters?Presented at the American Society of Clinical Oncology Annual Meeting 2008. Available at:http://www.asco.org. Accessed August 2008

10.1016/j.eururo.2008.06.082

Thông tin
Thông tin xuất bản

BJU International

Tập 103 Số 5

572-577

Thông tin tác giả